Nodal Marginal Zone Lymphoma · line 2 · R-Bendamustine for relapsed marginal zone lymphoma (post-rituximab failure)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-R-BENDAMUSTINE-RELAPSED-MZL |
| ID | IND-NMZL-2L-BR |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NODAL-MZL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
Standard-track 2L NMZL. Same regimen as SMZL 2L (REG-R-BENDAMUSTINE-RELAPSED-MZL).
Used By
Algorithms
ALGO-NMZL-2L- ALGO-NMZL-2L